Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nelson Tamala

Clinical Nurse Specialist, Family Health Chicago, IL Clinical Nurse Specialist

NPI 1043762453 CMS profile 10440081

4544 N Hazel St, Chicago, IL 60640

Open in the dashboard

General payments

$4,579

135 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nelson Tamala of Chicago, IL is reported in the CMS Open Payments database as having received $4,579 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,071 32
2024 General $1,111 39
2023 General $995 30
2022 General $839 22
2021 General $562 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nelson Tamala
  • Clinical Nurse Specialist, Family Health median
  • Middle half of Clinical Nurse Specialist, Family Health
  • National median

In program year 2025, general payments to Nelson Tamala were reported at $1,071. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.

Show as a table
Year Nelson Tamala Clinical Nurse Specialist, Family Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $562 $151 $46–$400 $132
2022 $839 $153 $37–$527 $149
2023 $995 $139 $50–$451 $160
2024 $1,111 $150 $46–$571 $164
2025 $1,071 $216 $57–$492 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $1,594 46 payments
  2. Neurocrine Biosciences, Inc. $1,259 49 payments
  3. Alkermes, Inc. $504 12 payments
  4. ITI, Inc. $385 6 payments
  5. Otsuka America Pharmaceutical, Inc. $271 4 payments
  6. Janssen Pharmaceuticals, Inc $252 7 payments
  7. E.R. Squibb & Sons, L.L.C. $122 1 payment
  8. ACADIA Pharmaceuticals Inc $113 6 payments
  9. Lundbeck LLC $54 3 payments
  10. Indivior Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,469 134 payments
  2. Education $109 1 payment
Products named General payments · program years 2021–2025
  1. INGREZZA Neuropsychiatry $990 44 payments
  2. Austedo XR $868 32 payments
  3. LYBALVI Cns $491 11 payments
  4. LYBALVI Cns $408 8 payments
  5. CAPLYTA $385 6 payments
  6. AUSTEDO $343 8 payments
  7. LYBALVI Cns $339 5 payments
  8. LYBALVI Cns $339 5 payments
  9. UZEDY $273 5 payments
  10. INGREZZA Neurology $269 5 payments
  11. Other $1,466 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

5,494

Median for Nurse Practitioner: 389

Drug cost

$1,154,476

Median for Nurse Practitioner: $21,885

Branded share of claims

9.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 103 $730,433
Austedo Xr Deutetrabenazine Brand 24 $151,533
Invega Sustenna Paliperidone Palmitate Brand 21 $65,189
Chlorpromazine Hcl Generic 95 $36,983
Quetiapine Fumarate Generic 635 $16,942
Divalproex Sodium Generic 519 $14,923
Fluphenazine Hcl Generic 109 $12,828
Rexulti Brexpiprazole Brand 15 $12,757
Clozapine Generic 182 $12,068
Olanzapine Generic 351 $11,447

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$238,765

Medicare's payments for the services billed

Medicare patients

517

Average age 68

Services billed

3,567

231 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Depression 57%
Arthritis 55%
COPD 45%
Alzheimer's or dementia 41%
Chronic kidney disease 36%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $392
$392 103 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $276
$276 24 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $232
  • Lundbeck LLC $15
$247 15 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $103
$103 — —
LYBALVI
  • Alkermes, Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Family Health in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record